Treatment of Wolff-Parkinson-White Syndrome
Catheter ablation of the accessory pathway is the definitive treatment for symptomatic patients with Wolff-Parkinson-White syndrome, particularly those with documented atrial fibrillation, syncope, or a short bypass tract refractory period (<250 ms). 1
Treatment Algorithm Based on Clinical Presentation
For Symptomatic Patients (Class I Recommendations)
Definitive therapy: Catheter ablation is recommended for all symptomatic patients, especially those with:
- History of atrial fibrillation with rapid ventricular response
- Syncope suggesting rapid heart rates
- Short accessory pathway refractory period (<250 ms)
- Multiple accessory pathways 2, 1
The guidelines consistently prioritize ablation because it addresses mortality risk—patients with WPW have a 0-0.6% annual risk of sudden death, primarily from pre-excited atrial fibrillation degenerating into ventricular fibrillation 2. Ablation has established safety and efficacy, though it may not prevent future atrial fibrillation in older patients 1.
For Acute Management During Arrhythmias
If hemodynamically unstable with pre-excited atrial fibrillation:
- Immediate electrical cardioversion to prevent ventricular fibrillation 2, 1
- This is non-negotiable—the risk of sudden death is too high to delay
If hemodynamically stable with pre-excited AF (wide QRS ≥120 ms):
- Intravenous procainamide or ibutilide to restore sinus rhythm 2, 1
- Alternatively, IV flecainide is reasonable 3
Critical contraindications—drugs that will kill these patients:
- NEVER give: digoxin, diltiazem, verapamil, beta-blockers, adenosine, or amiodarone in pre-excited atrial fibrillation 1
- These agents block the AV node, forcing conduction down the accessory pathway and accelerating ventricular rates, potentially causing ventricular fibrillation
The mechanism is straightforward: AV nodal blockers increase refractoriness of the normal pathway, encouraging preferential conduction through the accessory pathway with its potentially very short refractory period 2.
For Asymptomatic Patients (Incidental WPW Pattern)
This remains the most controversial area. The guidelines are more conservative:
Consider invasive risk stratification and possible ablation for:
- Young patients (<25 years) with high-risk occupations (pilots, athletes, drivers)
- Those with shortest pre-excited R-R interval <250 ms during induced AF
- Patients with multiple accessory pathways
- Associated Ebstein's anomaly 4
Risk stratification approach:
- Electrophysiology study to assess accessory pathway properties
- Inducibility of arrhythmias predicts future symptomatic events 5
- However, studies haven't been powered to show reduction in sudden death with prophylactic ablation 5
The practical reality: Most high-volume centers now offer ablation to younger asymptomatic patients after informed discussion, trading a very small immediate procedural risk (0.16% mortality) for elimination of future sudden death risk 6, 5.
Important Clinical Pitfalls
Location matters for ablation complexity:
- Anteroseptal pathways near the His bundle require cryoablation rather than radiofrequency to avoid AV block 7
- Ebstein's anomaly patients have 25% repeat ablation rates versus 6% overall 6
Age-related considerations:
- Older patients with asymptomatic WPW are less likely to receive appropriate risk stratification despite higher AF risk 8
- Ablation doesn't always prevent AF in older patients—additional antiarrhythmic therapy may be needed 1
The declining prevalence paradox:
- Two-thirds of European centers report declining WPW ablation volumes over the past decade 8
- Current prevalence is 0.36/1000, lower than historical 0.68-1.7/1000 6
- This likely reflects earlier intervention in the catheter ablation era
Pre-excited atrial fibrillation is the killer:
- Accounts for the sudden death risk in WPW
- Occurs in approximately 15% of WPW patients over 10 years 1
- Requires immediate cardioversion if unstable, or procainamide/ibutilide if stable 1
Pharmacologic Therapy (Rarely Used Now)
Chronic antiarrhythmic drugs are essentially obsolete given ablation success rates, but if ablation is refused or contraindicated:
- Class IC agents (flecainide, propafenone) for accessory pathway blockade
- Avoid drugs that only block the AV node
- No controlled trials support any specific agent 4
The evidence strongly favors ablation over chronic drug therapy for both efficacy and quality of life 1, 5.